Issued Patents All Time
Showing 1–13 of 13 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12397029 | Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors | Liang Deng, Jedd D. Wolchok, Taha Merghoub, Stewart Shuman, Weiyi Wang | 2025-08-26 |
| 12252702 | Recombinant poxviruses for cancer immunotherapy | Liang Deng, Jedd D. Wolchok, Stewart Shuman, Taha Merghoub, Ning-Sun Yang +3 more | 2025-03-18 |
| 12036279 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2024-07-16 |
| 11986503 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2024-05-21 |
| 11541087 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2023-01-03 |
| 11426460 | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang | 2022-08-30 |
| 11285209 | Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2022-03-29 |
| 11253560 | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors | Liang Deng, Jedd D. Wolchok, Taha Merghoub, Stewart Shuman, Weiyi Wang | 2022-02-22 |
| 10765711 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2020-09-08 |
| 10736962 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2020-08-11 |
| 10639366 | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang | 2020-05-05 |
| 10548930 | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors | Liang Deng, Jedd D. Wolchok, Taha Merghoub, Stewart Shuman, Weiyi Wang | 2020-02-04 |
| 10512662 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Weiyi Wang +1 more | 2019-12-24 |